Ladenburg kept a Buy rating on UroGen Pharma (URGN) with a $31 price target following a transfer of coverage. The firm sees a “de-risked path” to approval for UGN-102.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: